Physician profile
Jinfeng Jiang
NPI 1508434358
$5,112.71
in general payments reported to CMS, 2019-2025
10 companies · $2,392 in 2025
The $2,392 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $185 · 2024: $2,536 · 2025: $2,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,721 · Food and Beverage: $2,040 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,720.72 |
| Food and Beverage | $2,040.00 |
| Education | $167.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,400.63 | 2024-2025 | General - Kidney Stone Disease, General - Embolics, Rezum Generator |
| Coloplast Corp | $1,193.57 | 2024 | |
| Baxter Healthcare | $341.50 | 2025 | Perclot, Seprafilm |
| Janssen Biotech, INC. | $278.42 | 2024-2025 | Erleada, Carvykti, Rybrevant |
| Janssen Scientific Affairs, LLC | $265.26 | 2024-2025 | Erleada |
| Astellas Pharma US INC | $184.99 | 2022 | |
| Calyxo, INC. | $167.18 | 2024 | Cvac Aspiration System |
| Axonics, INC. | $139.31 | 2024 | Axonics, Bulkamid |
| Urogen Pharma, INC. | $125.00 | 2025 | |
| Endo USA, INC. | $16.85 | 2025 | Xiaflex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jinfeng Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.